Rtw Investments 13F: New $14M Stake in DFTX
Rtw Investments filed a Form 13F showing a new position of 300,000 shares in Definium Therapeutics, Inc.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rtw Investments opened a new position of 300,000 shares in Definium Therapeutics, Inc. ($DFTX), according to a 13F filing with the SEC dated May 15, 2026. It reported 300,000 shares worth $14.11 million at the end of the quarter.
Since the filing, $DFTX is up 7.2% after 1 week, up 13.2% after 1 month and up 52.9% to date (from the $20.99 close on May 15, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Rtw Investments opened a new position in Definium Therapeutics, Inc. (NasdaqGS: DFTX), purchasing 300,000 shares worth about $14.1 million as of the period ended May 15, 2026.
- Definium Therapeutics shares trade near $47.04, reflecting strong momentum as the biopharmaceutical company advances its brain health treatments.
- Several company insiders executed stock sales in late June 2026, while top executives also recorded option exercises and share acquisitions.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
Rtw Investments Builds a Position in Definium Therapeutics
Rtw Investments took a new stake in Definium Therapeutics, Inc. (NasdaqGS: DFTX), acquiring 300,000 shares during the period ended May 15, 2026. According to the fund's latest Form 13F filing with the SEC, the newly initiated holding carried an estimated value of $14.1 million based on its cost basis. Institutional filings offer a backward-looking snapshot of portfolio moves and may not reflect current holdings.
Rtw Investments vs. the S&P 500
Hypothetical returns from Rtw Investments's disclosed trades, not real profit or advice. How we model this.
Stock Trades Near Highs
Definium Therapeutics shares traded around $47.04, sitting close to the top end of its 52-week range that spans from a low of $9.35 to a high of $49.70. The stock continues to trade well above its 200-day moving average of $26.27, driven by recent clinical progress in its pipeline of brain health treatments.
Executive Insider Activity
Company insiders have been active in the market recently, with multiple executives recording share transactions in late June 2026. On June 25, 2026, Chief Financial Officer Brandi Roberts sold 3,013 shares at an average price of $45.03 for a total of $135,675.39 under a planned trading rule. On the same day, Chief Commercial Officer Matthew Wiley sold 2,867 shares for $129,101.01, Chief Legal Officer Mark Sullivan sold 13,008 shares for $585,750.24, and Chief Medical Officer Daniel Karlin sold 10,035 shares for $451,876.05. Earlier on June 22, 2026, CEO Robert Barrow and Chief Commercial Officer Matthew Wiley each acquired blocks of shares at zero cost.
Wall Street Coverage
Analyst firms maintain an upbeat view on the clinical biopharmaceutical company, anchored by a consensus recommendation of strong buy across 17 opinions. On October 9, 2026, JP Morgan initiated coverage with an overweight rating and an $84.00 price target. Earlier on September 15, 2026, Canaccord Genuity maintained a buy rating while lifting its price target to $78.00 from $64.00, and Baird kept an outperform rating with a target raised to $79.00 from $75.00.
About the Company
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in New York that focuses on developing treatments for brain health disorders. Its pipeline includes product candidates targeting generalized anxiety disorder, major depressive disorder, and autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. before changing its name in January 2026.
What's Ahead for Definium Therapeutics, Inc.
Investors will watch for the company's next financial results and pipeline updates when it reports earnings on November 5, 2026. Because 13F reports look backward, institutional portfolios may have shifted since the reporting date.
Related Filing Alerts
Source: Rtw Investments's 13F filing on $DFTX (May 15, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Rtw Investments 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts